Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Kilitch Drugs (India) Limited is a specialty and generic pharmaceutical manufacturer focused on the Indian domestic market and select export markets. The company operates manufacturing facilities producing formulations across therapeutic segments including cardiovascular, anti-diabetic, and anti-infective drugs. Recent 29% revenue growth and 83% net income growth suggest successful capacity expansion or market share gains, though negative free cash flow indicates ongoing capital investment phase.
Kilitch generates revenue by manufacturing and distributing generic pharmaceutical formulations at scale, leveraging India's cost-competitive manufacturing base. The company benefits from India's growing pharmaceutical demand driven by healthcare access expansion, chronic disease prevalence, and government initiatives. Gross margin of 47.3% reflects typical generic pharma economics with pricing power limited by competition but supported by brand recognition in therapeutic niches. Operating leverage comes from fixed manufacturing capacity utilization - the 14.3% operating margin should expand as recent capex ($0.5B, creating negative FCF) comes online and production scales.
Domestic pharmaceutical market growth rates in India (volume and pricing trends)
Capacity utilization rates at manufacturing facilities post-expansion
API and raw material cost inflation, particularly for imported ingredients
Regulatory approvals for new product launches or export market certifications
Government pharmaceutical pricing policies and National List of Essential Medicines updates
Indian government pharmaceutical pricing controls and National Pharmaceutical Pricing Authority interventions can cap prices on essential medicines, compressing margins on high-volume products
Increasing regulatory scrutiny from USFDA, EMA, and other export market regulators on Indian manufacturing facilities, with inspection failures causing revenue disruption
API supply chain concentration in China creates vulnerability to geopolitical tensions, logistics disruptions, or input cost spikes
Intense competition from large Indian generic manufacturers (Sun Pharma, Cipla, Dr. Reddy's) with greater scale, R&D budgets, and distribution reach
Pricing pressure in export markets as biosimilars and complex generics face competition from both innovator companies and other generic manufacturers
Limited differentiation in commodity generic segments forces competition primarily on price rather than therapeutic value
Negative free cash flow of -$0.3B indicates current capex ($0.5B) significantly exceeds operating cash flow ($0.2B), requiring either debt or equity financing to sustain investment pace
Working capital intensity typical of pharmaceutical distribution could strain liquidity if revenue growth decelerates while inventory and receivables remain elevated
Currency exposure on imported APIs and export receivables creates forex translation risk, particularly with INR volatility against USD and CNY
low - Pharmaceutical demand is relatively non-cyclical as healthcare needs persist regardless of economic conditions. However, discretionary healthcare spending and insurance penetration in India show modest GDP correlation. The 29% revenue growth significantly exceeds Indian GDP growth, suggesting market share gains or capacity-driven expansion rather than pure economic sensitivity.
Moderate sensitivity through two channels: (1) The 0.31 debt/equity ratio suggests manageable but non-trivial interest expense exposure to rate changes, particularly relevant given India's monetary policy cycle; (2) Valuation multiples compress when rates rise as healthcare stocks trade on long-duration cash flows. The current negative FCF phase increases sensitivity as the company may need external financing for ongoing capex.
Moderate - pharmaceutical distributors and hospital customers in India often operate on extended payment terms (60-90 days typical). Tighter credit conditions could stress working capital as receivables stretch. The strong 2.53 current ratio provides cushion, but accounts receivable quality matters. Export customers in emerging markets may face forex and credit constraints during global tightening cycles.
growth - The 29% revenue growth, 83% net income growth, and ongoing capex program attract growth investors betting on capacity expansion payoff and Indian pharmaceutical market penetration. The negative FCF and recent 22% six-month drawdown suggest momentum investors have rotated out, leaving longer-term growth investors focused on 2027-2028 margin expansion as new capacity ramps. The 2.7x P/S and 13.8x EV/EBITDA multiples are reasonable for high-growth pharma but require execution on capacity utilization.
moderate-to-high - The -22% six-month decline demonstrates significant volatility typical of mid-cap emerging market healthcare stocks. Beta likely elevated due to small-cap liquidity constraints, India-specific regulatory risks, and binary outcomes from facility inspections or product approvals. Currency volatility and commodity API price swings add to earnings unpredictability.